AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 62 min read$NEOG

Nassif Mikheal purchased $4K of NEOG (indirect holdings)

Nassif Mikheal (CEO) purchased 370 indirectly-held shares of NEOGEN CORP (NEOG) at $11.81 on 2026-08-04.

Original reporting
SEC EDGAR · Nassif Mikheal
Published Aug 6, 2026, 12:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 12:36 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$NEOG
Bullish
low confidence
Mentioned
$NEOG
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NEOGBullishLow
01

Why it matters

The CEO’s open-market purchase is a sentiment datapoint, but it does not include any new operational, financial, or regulatory information that would change valuation assumptions.

02

Market read

Traders may note the insider buy for sentiment, but the transaction size and lack of new fundamentals suggest limited trading impact.

03

What to watch

The article does not state the indirect holding structure details, and it provides no context on prior transactions or whether the purchase was part of broader compensation planning.

Relevance 3/10Novelty 3/10Timing: Form 4 filed 2026-08-06, covering a 2026-08-04 purchase.

Background

The article is a primary-source SEC Form 4 insider transaction disclosure for NEOGEN Corp.

Company-level read

Ticker impact

$NEOGBullishLow confidence
Context

NEOGEN CEO Nassif Mikheal bought 370 shares on 2026-08-04 for $4,369.70, disclosed via Form 4 filed 2026-08-06.

Expected impact

Likely limited, short-lived sentiment effect; no clear directional signal beyond optics.

Evidence & confidence

Form 4 insider buys can be read as confidence, but the disclosed size is small and the filing provides no new company performance or guidance.

Market effects

Sector

No sector-wide implications; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine liquidity or tax-related, and the indirect nature of the holdings reduces interpretability.

Key entities

  • issuer
    NEOGEN CORP

    Company whose CEO insider purchase is disclosed on Form 4.

  • insider
    Nassif Mikheal

    CEO and officer/director who reported an open-market purchase of 370 shares.

Read at source← All news

Related articles

AUG 8
$NEOGMedAI 8/10

Neogen (NEOG) Q4 2026 Earnings Call Transcript

Neogen (NEOG) reported fiscal Q4 2026 revenue of $225.3 million, up 4.3% in core growth, led by Food Safety. Adjusted gross margin rose to 49.7% and adjusted EBITDA grew 12% to $45.4 million. FY2027 guidance: revenue $880-$885 million and adjusted EBITDA $180-$182 million. The company plans a 50% R&D increase and a $140 million genomics divestiture for debt reduction.

fool.com6 min
JUL 31
$CORTMed

Biotech Stocks At 52-Week Highs- CORT +30%, NEOG +22% & BAX +7% With Quarterly Results, TRAX, XNCR

The following biotech stocks reached 52-week highs on July 30, 2026, driven by key catalysts such as positive quarterly reports or announced settlement agreements. Corcept Therapeutics Incorporated (CORT) Corcept is a biopharmaceutical company engaged in developing medications for metabolic, oncologic, and neurologic diseases. Shares surged over 30% on Thursday to a 52-week high of $122.21.

rttnews.com6 min
JUL 31
$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

rttnews.com6 min
JUL 30
$NEOGMed

NEOGEN CORP (NEOG): Results of Operations and Financial Condition

NEOGEN CORP (NEOG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 neog-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Neogen Reports Fourth Quarter and Full Fiscal Year 2026 Financial Results Delivered Strong Core Growth in Q4 FY26 with Food Safety Core Growth Highest Since FY23 • Fiscal fourth quarter 2026 revenue of $225.3 million represen

SEC EDGAR 8-K6 min
JUL 24
$NEOGMedAI 8/10

Neogen Chemicals Reports Q1 FY27 Net Profit Surge of 66.8% YoY to ₹17.11 Crore; Operational Revenue Up 34% at ₹250.29 Crore

Neogen Chemicals reported unaudited consolidated Q1 FY27 results for the quarter ended June 30, 2026. Revenue from operations rose 34.04% YoY to ₹250.29 crore. Net profit increased 66.76% YoY to ₹17.11 crore, with operating margin at 19.35%. The company said net worth rose to ₹984.47 crore and debt equity improved to 1.40x. Shares last traded on BSE near ₹2,063.

equitybulls.com4 min